Targeted CXCR4 diagnosis and treatment integrated reagent based on combined administration strategy
Through combined dosing strategies and integrated reagents for targeting CXCR4 diagnosis and treatment, targeting CXCR4 inhibitors with specific radionuclides has been solved, and the problem of serious side effects of CXCR4 inhibitors in the prior art has been achieved, and the cancer expression of CXCR4 is achieved. Efficient detection and treatment, especially in imaging and treatment of pancreatic and prostate cancers, significantly improved.
Patent Information
- Application Number
- CN202411210017.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-06
AI Technical Summary
The existing radiolabeled CXCR4 inhibitors have side effects due to physiological organ uptake of CXCR4 expression in the treatment, and the treatment success rate is low, especially when using 225Ac, the salivary glands and lacrimal glands are severely damaged, making it difficult to achieve early detection and treatment, especially in the prostate. In management of cancer.
Using targeted CXCR4 diagnostic and treatment integrated reagents based on a combined dosing strategy, including compounds (a) and compounds (b), new compounds are discovered through PET imaging as tracers and therapeutic agents, with preferred radionuclides such as 149Tb, 153Gd, 211At, 223Ra, etc., combined with conventional imaging methods, were prepared in a molar ratio of 50:1 to 100:1, and were used for the diagnosis and treatment of cancers expressing CXCR4, especially pancreatic cancer.
Achieve effective detection and treatment of CXCR4-expressed cancers in nuclear medicine, reducing side effects, especially in imaging and treatment of pancreatic and prostate cancers, showing good imaging quality and half-life, and reducing kidneys and muscles radioactive uptake improves the safety and effectiveness of treatment.
Smart Images

Figure CN119074968A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to radiolabeled compounds for selective imaging or treatment of cancer, in particular to targeting compounds for cancers that highly express CXCR4. Background Art
[0002] At present, CXCR4 is a specific receptor for the chemokine stromal cell-derived factor-1 (SDF-1 / CXCL12), which is essentially a cell-expressed albumin that plays an important role in the occurrence, chemotaxis and metastasis of tumor cells. CXCR4 is expressed in 75% of tumors (including pancreatic cancer, breast cancer, lung cancer, prostate cancer and colon cancer, etc.). In the current therapeutic application of radiolabeled CXCR4 inhibitors, organs with physiological CXCR4 expression have been proven to be dose-limiting, thereby minimizing the success rate of treatment. In particular, the high renal and salivary gland uptake of radiolabeled CXCR4 inhibitor substances is significant, which can cause considerable side effects in the case of therapeutic applications. The large accumulation of CXCR4 ligands in the salivary glands and lacrimal glands leads to considerable side effects. However, the reduction of salivary and lacrimal gland uptake has not yet been achieved and is still described as critical and dose-limiting in early clinical work. The salivary glands and lacrimal glands are severely and partially irreversibly damaged, especially when used. 225 Therefore, there remains a need for improved CXCR4 ligands that provide advantageous options for the detection, treatment and management of CXCR4-expressing cancers, particularly prostate cancer.
[0003] The present invention proposes various disease states that can be used as tracers, imaging agents in nuclear medicine and for the treatment of cancers expressing CXCR4, in particular pancreatic cancer. Summary of the invention
[0004] The purpose of the present invention is to provide an integrated diagnostic and therapeutic reagent targeting CXCR4 based on a combined drug administration strategy. Through PET imaging, new compounds are discovered to be used as tracers and imaging agents in nuclear medicine and for the treatment of cancers expressing CXCR4, so as to achieve the application effects proposed in the above-mentioned background technology.
[0005] To achieve the above object, the present invention provides the following technical solutions:
[0006] An integrated CXCR4-targeted diagnostic and therapeutic reagent based on a combined drug delivery strategy, comprising compound (a) and compound (b):
[0007] Compound (a) is a compound having the following formula (I) or (II), or a stereoisomer, a pharmaceutically acceptable salt or a solvate thereof:
[0008]
[0009] Compound (b) is selected from
[0010] Wherein: T is a structural unit of a radioactive element or a radioactive metal chelator or a radioactive metal nuclide; preferably, T is 149 Tb, 153 Gd, 211 At 213 Bi, 223 Ra, 225 Ac, 230 U. 47 Sc, 64 Cu, 67 Cu, 90 Y. 152 Tb, 153 Sm, 161 Tb, 177 Lu, 186 Re, 188 Re, 203 Pb, 212 Pb, 18 F. 44 Sc, 45 Ti, 52 Mn, 52 Fe, 59 Fe, 60 Cu, 6l Cu, 62 Cu, 64 Cu, 66 Cu, 67 Cu, 66 Ga, 68 Ga, 82 Rb, 86 Y. 89 Zr, 152 Tb, 155 Gd, 157 Gd, 67 Ga, 99m Tc, 111 In, 123 I. 124 I. 125 I. 131 I. 153 Sm, 155 Tb, 165 2. 191 Pt.
[0011] Preferably, the compound (b) is selected from
[0012] The compounds of the present invention may contain one or more than one radionuclide, preferably one radionuclide. These radionuclides are preferably suitable for use as radioactive imaging agents or as a therapy for the treatment of proliferating cells, such as cancer cells expressing CXCR4, in particular pancreatic cancer cells expressing CXCR4. According to the present invention, they are referred to as "metal complexes" or "radiopharmaceuticals".
[0013] The imaging method may be a conventional method in the art, for example, the imaging method may be positron emission tomography (PET) or SPECT.
[0014] The present invention also provides the integrated diagnostic and therapeutic reagent targeting CXCR4 based on the combined drug administration strategy, which is any one of the groups ZT-01-04:
[0015]
[0016]
[0017] The targeted CXCR4 integrated diagnosis and treatment reagent of the present invention, wherein the molar ratio of compound (a) to compound (b) is 50:1 to 100:1, preferably any range of 50:1 to 95:1, 50:1 to 90:1, 50:1 to 85:1, 65:1 to 80:1, 70:1 to 80:1, 75:1 to 80:1; more preferably, the ratio is 50:1 or 75:1 to 85:1.
[0018] Preferably, the combined administration can be any group, and the T is preferably 131 I. 18 F. 211 At.
[0019] Compounds according to the present invention can be formulated with common excipients and carriers in other active substances and pharmaceutical compositions under suitable circumstances. For example, according to the preparation talcum powder, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous and non-aqueous carriers, fat bodies of animal or plant origin, paraffin derivatives, glycols (particularly polyethylene glycol), various plasticizers, dispersants or emulsifiers, pharmaceutically compatible gases (such as air, oxygen, carbon dioxide, etc.), preservatives to be prepared. In order to prepare liquid preparations, additives such as sodium chloride solution, ethanol, sorbitol, glycerol, olive oil, almond oil, propylene glycol or ethylene glycol can be used.
[0020] The phrase "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication, and with a reasonable benefit / risk.
[0021] "Patient" includes animals, such as humans, monkeys, cows, horses, cats or dogs. Animals can be mammals, such as non-primates and primates (e.g., monkeys and humans). In one embodiment, the patient is a human.
[0022] The use of an integrated diagnostic and therapeutic reagent targeting CXCR4 based on a combined drug delivery strategy in the preparation of a drug for treating, improving or preventing cancers expressing CXCR4 and / or their metastases.
[0023] The use of an integrated diagnostic and therapeutic reagent targeting CXCR4 based on a combined drug delivery strategy in the preparation of a reagent for diagnosing or assisting in the diagnosis of cancers and / or their metastases that express CXCR4.
[0024] The term "CXCR4-expressing cancer and / or its metastases" as used within the meaning of the present invention relates to any cancer whose cancer cells express CXCR4 and its respective metastases. Preferably, the cancer (or cancer cells) that can be treated according to the present invention is selected from pancreatic cancer, prostate cancer, neuroendocrine cancer, colon cancer, lung cancer and breast cancer. In a particularly preferred aspect of the present invention, the cancer expressing CXCR4 is prostate cancer or breast cancer, in particular prostate cancer.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] The present inventors have discovered novel CXCR4-targeted diagnostic and therapeutic agents, which are useful and advantageous radiopharmaceuticals and can be used as tracers, imaging agents and for treating various disease states of cancers expressing CXCR4, especially high-expressing cancers, in nuclear medicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Injection of tumor-bearing mice 18 One of the representative PET images 3 hours after F-labeling of the integrated diagnostic and therapeutic reagent targeting CXCR4;
[0028] Figure 2 Injection of tumor-bearing mice 18 The second representative PET image 3 hours after F-labeling of the integrated diagnostic and therapeutic reagent targeting CXCR4;
[0029] Figure 3 Injection of tumor-bearing mice 18 Representative PET images 3 h after F-CXCR4. DETAILED DESCRIPTION
[0030] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0031] It should be further understood that the term “and / or” used in the specification of this application and the appended claims refers to any combination and all possible combinations of one or more of the associated listed items, and includes these combinations.
[0032] Synthesis of compound (a)
[0033]
[0034] (1) DCM was added into a solid phase tube containing CTC resin (0.11 mmol, 0.55 g, 0.20 mmol / g) and Fmoc-Lys(Dde)-OH (0.06 g, 0.11 mmol, 1.0 eq.), and nitrogen was continuously blown;
[0035] (2) DIEA (6.0 eq.) was added dropwise to the solid phase tube and stirred for 2 h;
[0036] (3) Add MeOH (0.6 mL) to the solid phase tube and stir for 0.5 h;
[0037] (4) Rinse the resin with DMF and dry, repeat 5 times;
[0038] (5) Add 20% piperidine / DMF (v / v) to the solid phase tube and react for 0.5 h;
[0039] (6) Rinse the resin with DMF and dry, repeat 5 times;
[0040] (7) Add Fmoc-amino acid solution to the solid phase tube, mix for 30 seconds, add coupling agent and continue the reaction for 1 hour, continue to blow nitrogen, and repeat steps (4) to (7);
[0041] (8) The reaction product was transferred to a DMF solution, and TSTU and DIPEA were added in sequence under a nitrogen atmosphere. The mixture was stirred for 0.5 h, and then 6, Tz was added to react. The reaction was detected to the end point, and the compound (a) without the introduction of the radionuclide label was purified by HPLC procedure 1.
[0042] The HPLC procedure 1 used a mobile phase system: 0.1% TFA in ultrapure water as solvent A, and 0.1% TFA in acetonitrile solution as solvent B. For the HPLC procedure 1, the mobile phase was 40% solvent A and 60% solvent B from 0 to 2 min, and in the following 20 min, the mobile phase was 47% solvent A and 53% solvent B. Compound (a) without the introduction of nuclide label was obtained.
[0043] Synthesis of compound (b)
[0044] Synthetic route 1
[0045]
[0046] 1. 1 (1.0 g, 7.9 mmol) was slowly added to 25 mL THF solution containing sodium hydride (0.65 g 60% mineral oil dispersion, 15.9 mmol). It was refluxed and stirred for 1 h, then a solution of iodoacetic acid (1.45 g, 7.9 mmol) in 25 mL THF was added, and refluxed for 4 h, and the reaction was monitored to the end point. Then, the reaction was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in 20 mL of 10% NaOH solution and extracted with Et2O (2×25 mL). The aqueous solution was adjusted to pH=4 by adding 6 mol / L HCl and extracted again with DCM (2×25 mL). In addition, the organic phase was dried, filtered, and concentrated by rotary evaporator. The DCM extract was 2.
[0047] 2. HATU and DIPEA were added to the DMF solution of 2 in a nitrogen atmosphere, stirred for 0.5 h, and then 3 was added. The reaction system was stirred at room temperature overnight and extracted with ethyl acetate. After evaporation of the solvent, 4 was purified by column chromatography.
[0048] 3. Dissolve 4 (180 mg, 1.1 mmol), tosyl chloride (262 mg, 1.4 mmol) and triethylamine (214 mg, 2.1 mmol) in acetonitrile (6 mL) and monitor the reaction progress by TLC. After stirring at room temperature for 1 hour, filter the reaction mixture and concentrate by rotary evaporation. Purify the pure product by column chromatography to obtain 5 (compound b). Using HPLC procedure 1, retention time: 25.3 minutes.
[0049] Synthetic route 2
[0050]
[0051] (1) HATU and DIPEA were added to a DMF solution of 1 in a nitrogen atmosphere, and the mixture was stirred for 0.5 h. Then, 2 was added to react. The reaction system was stirred at room temperature overnight, extracted with ethyl acetate, and after evaporation of the solvent, 3 was purified by column chromatography;
[0052] (2) 3 (0.5 g, 2.95 mmol) was converted to 4 using a recycle / trap approach. The (E)-isomer was liberated from 10% AgNO3 silica gel containing 50 mL of 30% ammonium hydroxide solution and 50 mL of DCM by stirring for 10 min. The suspension was filtered and the organics were separated, dried (MgSO4) and concentrated to give a pale yellow oil. The crude product was purified by column chromatography to give high purity 4 using HPLC procedure 1, retention time: 13.9 min.
[0053] Example 1: Synthesis of Radiolabeled Targeting Agents
[0054] (1) Synthesis of ZT-01 parts a and b
[0055] The synthesis of compound (a) was carried out according to the synthesis route, and radioactive iodine-124 or iodine-131 was labeled at the ortho-C of the tyrosine residue of compound a without the introduction of the radionuclide label, so as to complete the synthesis of part a in ZT-01. Using HPLC program 1, retention time: 10.2 minutes;
[0056] The compound (b) synthesized by the synthetic route 1 is radiolabeled by adding a 7% sodium bicarbonate solution of the compound (b)① into a reaction flask. 211 At aqueous solution. Add 0.1 mol / L KI solution to the mixture, and allow the mixture to stand at room temperature for 30 minutes to complete the synthesis of part b in ZT-01. Use HPLC procedure 2, retention time: 11.5 minutes. HPLC procedure 2 uses a mobile phase system: 0.1% TFA in ultrapure aqueous solution as solvent A, and 0.1% TFA in acetonitrile solution as solvent B. For HPLC procedure 2, 0-2min, the mobile phase is 40% solvent A and 60% solvent B. Increase to 95% solvent A and 5% solvent B (gradient elution) in the next 20min.
[0057] (2) Synthesis of ZT-02 parts a and b
[0058] The synthesis of compound (a) was carried out according to the synthesis route, and radioactive iodine-124 or iodine-131 was labeled at the ortho-C of the tyrosine residue of compound a without the introduction of the radionuclide label, so as to complete the synthesis of part a in ZT-02. Using HPLC program 1, retention time: 10.2 minutes;
[0059] The compound (b) synthesized by the second synthetic route is radiolabeled. The specific method is as follows: the compound (b) ② and a methanol solution of [Cu(py)4OTf2] / 3,4,7,8-tetramethyl-1,10-phenanthroline are added to a reaction flask, and then 77 Br aqueous solution was mixed and stirred at room temperature for 30 minutes to complete the synthesis of part b in ZT-02. Using HPLC procedure 2, retention time: 12.1 minutes.
[0060] Example 2: In vitro competitive binding assay and internalization rate
[0061] MultiScreen was washed with 100 μl PBS containing 1% BSA per well at room temperature. HTS -DV filter plate was incubated for 30 minutes. After removing the PBS / BSA solution, 1×10 5 C4-2 cells. 0.75 nM 18 F-labeled CXCR4-HBED dimer ( 18 F-CXCR4) was used as a standard to determine the inhibitory potency of the synthesized compounds. All unlabeled compounds were dissolved in Opti-MEM at the following concentrations in a volume of 300 μL: OnM, 0.5nM, 1nM, 2.5nM, 5nM, 10nM, 25nM, 50nM, 100nM, 500nM, 1000nM and 5000nM. Then, 3 μL of radiolabeled compound was added and 50 μL of this mixture was taken to obtain a 0.75nM concentration of radiolabeled ligand. After incubation at 37°C for 45 minutes, the cells were washed twice with PBS on a multi-screen vacuum manifold and the cell-bound radioactivity was measured using a gamma counter. 18 F-labeled CXCR4-HBED dimer was used as a reference to determine the inhibitory potency. K was calculated using a nonlinear regression algorithm (Graph Pad Prism 5.01 software). i The experiment was performed four times.
[0062] To determine the specific internalization rate, 24-well plates were incubated with 0.1% poly-L-lysine in PBS for 20 min at room temperature and washed once with PBS. In the next step, 1 × 10 51mL RPMI medium of C4-2 cells and cultured overnight. The conditions for each compound during the experiment were: incubation at 37°C or 4°C with or without blocking the receptor by 2-(phosphonomethyl)glutaric acid (2-PMPA; Axxora) at a final concentration of 500μM. Then, the cells were incubated with 250uL of 30nM labeled compound solution. The plate was incubated in a 37°C water bath or on ice at 4°C for 45 minutes. Then, the cells were washed three times with 1mL ice-cold PBS and incubated with glycine (50mM in HCl, pH2.8) for 5 minutes. After an additional washing step with 1mL ice-cold PBS, the cells were lysed with 0.5mL of 0.3M NaOH, collected and measured for radioactivity with a gamma counter for 1 minute. By subtracting the corresponding uptake under blocking conditions, the binding to 10 cells (IA / 10 6 Specific cellular uptake was determined as a percentage of the initial added radioactivity per 100 cells. All experiments were performed in triplicate. i The assay showed that the synthetic ligand had nanomolar binding affinity for CXCR4. Binding assays showed that the probe had good affinity for the LNCaP cell line. The K i =1.52 μM. As shown in Table 1.
[0063] Table 1 IC values of preferred compounds in LNCaP cells 50 value
[0064]
[0065] Example 3: In vivo PET imaging studies
[0066] Tumor-bearing nude mice were placed in an anesthesia box and pre-anesthetized with 3% isoflurane-oxygen mixed gas for 5-10 minutes. The mice were placed on the scanning bed, their limbs were fixed with medical tape, and anesthesia was maintained with isoflurane-oxygen mixed gas. The position was adjusted so that it was in the center of the micro-PET scanner's field of view. A 1 mL insulin syringe was used to draw the diluted saline solution. 18 The target probe solution labeled with F was measured for radioactivity and the measurement time was recorded. After the tail vein was injected into the tumor-bearing mouse, the injection time was recorded, and then the residual radioactivity in the insulin syringe was measured and the measurement time was recorded. Static scanning was performed for 10 minutes at 30, 90, and 180 minutes after the injection of the probe, and the acquisition mode was 3D mode. The three-dimensional ordered subset expectation maximization (3D OSEM) algorithm was used for image reconstruction. The results are shown in Figure 1 , Figure 2 .
[0067] The results showed that: using the diagnostic probe of this example, the 3h representative PET imaging image showed that over time, the LNCaP tumor-bearing mouse model had obvious uptake at the tumor location, and there was no downward trend, and the uptake in the liver, kidneys and muscles was less. Compared with similar probes 18 F-CXCR4( Figure 3 ), with a longer half-life and imaging quality, and better uptake in the kidney.
[0068] As can be seen from the above, the inventors have discovered new integrated diagnostic and therapeutic agents targeting CXCR4, which are useful and advantageous radiopharmaceuticals and can be used as tracers, imaging agents and for treating various disease states of cancers expressing CXCR4, especially high-expressing cancers, in nuclear medicine.
[0069] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "examples", "specific examples" or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and the features of different embodiments or examples, unless they are contradictory.
[0070] In the drawings of the embodiments disclosed in the present invention, only the structures involved in the embodiments disclosed in the present invention are involved, and other structures can refer to the general design. In the absence of conflict, the same embodiment and different embodiments of the present invention can be combined with each other.
[0071] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. Integrated diagnostic and therapeutic reagent targeting CXCR4 based on combined drug delivery strategy, It is characterized in that Comprising compound (a) and compound (b): Compound (a) is a compound having the following formula (I) or (II), or a stereoisomer, a pharmaceutically acceptable salt or a solvate thereof: Compound (b) is selected from Wherein: T is a structural unit of a radioactive element or a radioactive metal chelator or a radioactive metal nuclide; preferably, T is 149 Tb, 153 Gd, 211 At 213 Bi, 223 Ra, 225 Ac, 230 U. 47 Sc, 64 Cu, 67 Cu, 90 Y. 152 Tb, 153 Sm, 161 Tb, 177 Lu, 186 Re, 188 Re, 203 Pb, 212 Pb, 18 F. 44 Sc, 45 Ti, 52 Mn, 52 Fe, 59 Fe, 60 Cu, 6l Cu, 62 Cu, 64 Cu, 66 Cu, 67 Cu, 66 Ga, 68 Ga, 82 Rb, 86 Y. 89 Zr, 152 Tb, 155 Gd, 157 Gd, 67 Ga, 99m Tc, 111 In, 123 I. 124 I. 125 I. 131 I. 153 Sm, 155 Tb, 165 2. 191 Pt.
2. The targeting agent according to claim 1, Features: The compound (b) is selected from 3. CXCR4-targeted diagnostic and therapeutic integrated reagents based on combined drug delivery strategy, any one of the following groups: ZT-01-04:
4. The integrated diagnostic and therapeutic reagent targeting CXCR4 based on a combined drug administration strategy according to any one of claims 1 to 3, It is characterized in that The molar ratio of compound (a) to compound (b) is 50:1 to 100:1, preferably any range of 50:1 to 95:1, 50:1 to 90:1, 50:1 to 85:1, 65:1 to 80:1, 70:1 to 80:1, 75:1 to 80:1; more preferably, the ratio is 50:1 or 75:1 to 85:
1.
5. The integrated diagnostic and therapeutic reagent targeting CXCR4 based on a combined drug delivery strategy according to any one of claims 1 to 3, It is characterized in that The combined administration may be any group, and T is preferably 131 I. 18 F. 211 At.
6. Use of the CXCR4-targeted integrated diagnostic and therapeutic reagent based on a combined drug administration strategy as described in any one of claims 1 to 5 in the preparation of a drug for treating, improving or preventing cancer expressing CXCR4 and / or its metastatic tumors.
7. Use of the CXCR4-targeted integrated diagnostic and therapeutic reagent based on a combined drug delivery strategy as described in any one of claims 1 to 5 in the preparation of a reagent for diagnosing or assisting in the diagnosis of cancers expressing CXCR4 and / or their metastases.
8. The use according to claim 6 or 7, It is characterized in that The cancer expressing CXCR4 and / or its metastasis is selected from pancreatic cancer, brain glioma, conventional renal cell carcinoma, bladder transitional cell carcinoma, testicular-embryonal carcinoma, neuroendocrine cancer, colon cancer, brain tumor, prostate cancer, bile duct cancer, ovarian cancer or breast cancer; preferably pancreatic cancer, brain glioma or breast cancer; more preferably pancreatic cancer.
